Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | GPR39 | O43194 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13288607 | 0.92 | GSK3B (0.52) | GSK3BCDK2MAP4K1CCNA2CCNA1 | |
| SCHEMBL13305702 | 0.91 | GSK3B (0.53) | GSK3BCDK2CCNA2CCNA1MAPK10 | |
| SCHEMBL13305704 | 0.91 | GSK3B (0.53) | GSK3BCDK2MAP4K1CCNA2CCNA1 | |
| SCHEMBL12953772 | 0.90 | GSK3B (0.68) | GSK3BCDK2MAP4K1CCNA2CCNA1 | |
| SCHEMBL12953665 | 0.86 | GSK3B (0.63) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305409 | 0.85 | GSK3B (0.58) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL14050780 | 0.85 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305401 | 0.84 | GSK3B (0.56) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL14043290 | 0.84 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL14050761 | 0.83 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |